Drug Profile
Research programme: tolerance-inducing therapeutics - MIVAC Development
Alternative Names: CTA1R7K-COL-DD; CTA1R7K-X-DDLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator MIVAC Development
- Class Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Sweden (Intranasal)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Sweden (Intranasal)
- 28 May 2011 Preclinical trials in Autoimmune disorders in Sweden (Intranasal)